---
title: "Understanding the Market | CSPC PHARMA rose nearly 3% as Mesalazine enteric-coated tablets received drug registration approval, further enriching the product line in the field of immune system therapy"
description: "CSPC PHARMA rose nearly 3%, as of the time of publication, it increased by 2.04%, trading at HKD 8.02, with a transaction volume of HKD 311 million. In terms of news, recently, CSPC PHARMA announced t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/247734450.md"
published_at: "2025-07-09T02:18:02.000Z"
---

# Understanding the Market | CSPC PHARMA rose nearly 3% as Mesalazine enteric-coated tablets received drug registration approval, further enriching the product line in the field of immune system therapy

> CSPC PHARMA rose nearly 3%, as of the time of publication, it increased by 2.04%, trading at HKD 8.02, with a transaction volume of HKD 311 million. In terms of news, recently, CSPC PHARMA announced that its developed mesalazine enteric-coated tablets (0.5g) have obtained the drug registration approval issued by the National Medical Products Administration of the People's Republic of China, and are considered to have passed the consistency evaluation of quality and efficacy for generic drugs. Mesalazine primarily exerts its therapeutic effect by regulating inflammation-related indicators that cause intestinal mucosal inflammation, inhibiting the synthesis of inflammatory prostaglandins and the formation of inflammatory mediators leukotrienes, thereby achieving anti-inflammatory effects, with better therapeutic effects on the connective tissue of inflamed intestinal walls. This product is suitable for the treatment of ulcerative colitis, including treatment during acute episodes and maintenance therapy to prevent recurrence, as well as for the treatment of acute episodes of Crohn's disease. This product has a significant inhibitory effect on intestinal wall inflammation and is a widely used aminosalicylate anti-inflammatory drug globally. The approval of this product will further enrich the group's product line in the field of immune system therapy

According to Zhitong Finance APP, CSPC PHARMA (01093) rose nearly 3%, and as of the time of writing, it was up 2.04%, trading at HKD 8.02, with a transaction volume of HKD 311 million.

In terms of news, recently, CSPC PHARMA announced that its developed mesalazine enteric-coated tablets (0.5g) have obtained the drug registration approval issued by the National Medical Products Administration of the People's Republic of China, and are considered to have passed the consistency evaluation of quality and efficacy for generic drugs.

Mesalazine primarily exerts its therapeutic effect by regulating inflammation-related indicators that cause intestinal mucosal inflammation, inhibiting the synthesis of inflammatory prostaglandins and the formation of inflammatory mediators leukotrienes, thereby achieving anti-inflammatory effects. It is particularly effective in treating the connective tissue of inflamed intestinal walls. This product is suitable for the treatment of ulcerative colitis, including treatment during acute episodes and maintenance therapy to prevent recurrence, as well as for treating acute episodes of Crohn's disease. The product has a significant inhibitory effect on intestinal wall inflammation and is a widely used aminosalicylate anti-inflammatory drug globally.

The approval of this product will further enrich the group's product line in the field of immune system therapy

### Related Stocks

- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 石藥集團獲得監管機構的批准以啓動藥物試驗 | 石藥集團獲得監管批准開始藥物試驗 | [Link](https://longbridge.com/en/news/276035104.md) |
| 聯想因 ‘人工智能的普及化’ 而措手不及 | 聯想在最新的財季報告中顯示利潤下降 21%，並因人工智能計算市場的變化而承擔了 2.85 億美元的重組費用。由於內存價格上漲，公司毛利率下降。此次重組反映了聯想在人工智能普及方面適應緩慢，從雲端設施的人工智能訓練轉向本地人工智能推理。儘管其 | [Link](https://longbridge.com/en/news/275904944.md) |
| 中國神華能源獲得證券監管機構批准其股份配售計劃 | 中國神華獲得證券監管機構對增發計劃的批准 | [Link](https://longbridge.com/en/news/275851575.md) |
| 野村證券將閲文集團的評級從中性上調至買入，並將目標價從 33 港元上調至 47 港元 | 野村將閲文集團評級從中性上調至買入，目標價從 33 港元調整至 47 港元 | [Link](https://longbridge.com/en/news/275882954.md) |
| 中國的聯想集團警告稱內存緊縮可能會 ‘持續’，並寄望於通過人工智能實現反彈 | 聯想集團，全球最大的個人電腦製造商，因全球內存緊缺報告利潤下降 21%，並警告其影響將持續。儘管收入增長 18% 至 222 億美元，但高昂的內存成本影響了利潤，淨收入為 5.46 億美元。聯想向人工智能驅動設備的轉型實現了 72% 的收入 | [Link](https://longbridge.com/en/news/275760673.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.